Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia

Diabetologia

Volumn 60, Issue 3, 2017, Pages 531-540

  Craig, Colleen M ^a   Liu, Li Fen ^a   Deacon, Carolyn F ^b   Holst, Jens J ^b   McLaughlin, Tracey L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bariatric complication; GLP 1; Hyperinsulinaemic hypoglycaemia; Hypoglycaemia; Late dumping syndrome; Nesidioblastosis; Neuroglycopenia; NIPHS; Noninsulinoma pancreatogenous hypoglycaemia syndrome; Post bariatric hypoglycaemia; Roux en Y gastric bypass; RYGB

Indexed keywords

EXENDIN 9 39; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HYPERGLYCEMIC AGENT; INCRETIN; INSULIN; PLACEBO; UNCLASSIFIED DRUG; EXENDIN 9; GASTRIC INHIBITORY POLYPEPTIDE; PEPTIDE FRAGMENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPOGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; GASTRIC BYPASS SURGERY; GLUCOSE TOLERANCE TEST; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTRIC BYPASS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIA; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SURVEYS AND QUESTIONNAIRES;

EID: 85006093261     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4179-x     Document Type: Article

References (48)

1. Ogden C, Carroll M, Kit B, Flegal K (2014) Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311:806–814
2. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W (2009) Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff 28:822–831
3. Sjostrom L, Lindroos AK, Peltonen M et al (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683–2693
4. Adams TD, Gress RE, Smith SC et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357:753–761
5. Pories WJ, Swanson MS, MacDonald KG et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350
6. Schauer PR, Burguera B, Ikramuddin S et al (2003) Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238:467–484
7. Rubino F, Nathan D, Eckel R et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:861–877
8. Kashyap SR, Bhatt DL, Wolski K et al (2013) Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36:2175–2182
9. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ (2007) Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3:597–601
10. Holst J, Madsbad S (2016) Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis 12:1236–1242
11. Vidal J, De Hollanda A, Jiménez A (2016) GLP-1 is not the key mediator of the health benefits of metabolic surgery. Surg Obes Relat Dis 12:1225–1229
12. Marsk R, Jonas E, Rasmussen F, Naslund E (2010) Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986-2006 in Sweden. Diabetologia 53:2307–2311
13. Kellog TA, Bantle JP, Leslie DB et al (2008) Postgastric bypass hyperinsulinemic hypoglycaemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 4:492–499
14. Gribsholt SB, Pedersen AM, Svensson E, Thomsen RW, Richelsen B (2016) Prevalence of self-reported symptoms after gastric bypass surgery for obesity. JAMA Surg 151:504–511
15. Kefurt R, Langer FB, Schindler K et al (2015) Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test. Surg Obes Relat Dis 11:564–569
16. Valderas J, Ahuad J, Rubio L, Escalona M, Pollak F, Maiz A (2012) Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels. Obes Surg 22:582–586
17. Spanakis E, Gragnoli C (2009) Successful medical management of status post-Roux-en-Y-gastric-bypass hyperinsulinemic hypoglycaemia. Obes Surg 19:1333–1334
18. Moreira R, Moreira R, Machado N, Gonçalves T, Coutinho W (2008) Post-prandial hypoglycaemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg 18:1618–1621
19. McLaughlin TL, Peck M, Holst JJ, Deacon C (2010) Reversible hyperinsulinemic hypoglycaemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 95:1851–1855
20. Craig C, Lamendola C, Deacon C, Holst J, McLaughlin T (2015) The use of gastrostomy tube for the long-term remission of hyperinsulinemic hypoglycaemia after Roux-en-Y gastric bypass – a case report. AACE Clin Case Rep 1:e84–e87
21. Fernández-Esparrach G, Lautz D, Thompson C (2016) Peroral endoscopic anastomotic reduction improves intractable dumping syndrome in Roux-en-Y gastric bypass patients. Surg Obes Relat Dis 6:36–40
22. Lee CJ, Brown T, Magnuson TH et al (2013) Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycaemia. J Clin Endocrinol Metab 98:1208–1212
23. Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128–2137
24. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV (2005) Hyperinsulinemic hypoglycaemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353:249–254
25. Kim SH, Abbasi F, Lamendola C, Reaven GM, McLaughlin T (2010) Glucose-stimulated insulin secretion in gastric bypass patients with hypoglycaemic syndrome: no evidence for inappropriate pancreatic beta cell function. Obes Surg 20:1110–1116
26. Patti ME, McMahon G, Mun EC et al (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240
27. Falken Y, Hellstrom PM, Holst JJ, Nasund E (2011) Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96:2227–2235
28. Marathe CS, Rayner CK, Jones KL, Horowitz M (2013) Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36:1396–1405
29. Goldfine A, Mun E, Devine E et al (2007) Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 92:4678–4685
30. Malin SK, Kashyap SR (2015) Differences in weight loss and gut hormones: Roux-en-Y gastric bypass and sleeve gastrectomy surgery. Curr Obes Rep 4:279–286
31. Salehi M, Prigeon RL, D’Alessio DA (2011) Gastric bypass surgery enhances glucagon-like peptide-1 stimulated postprandial insulin secretion in humans. Diabetes 60:2308–2314
32. Salehi M, Gastaldelli A, D’Alessio D (2014) Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycaemia after gastric bypass. Gastroenterology 146:669–680
33. Ahren B, Holst JJ, Mari A (2003) Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care 26:2860–2864
34. Deary IJ, Hepburn DA, MacLeod KM, Frier BM (1993) Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 36:771–777
35. Hepburn DA, Deary IJ, Frier BM, Patrick AW, Quinn JD, Fisher BM (1991) Symptoms of acute insulin-induced hypoglycaemia in humans with and without IDDM. Diabetes Care 14:949–957
36. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans. Diabetes 43:535–539
37. Lindgren O, Carr RD, Deacon CF et al (2011) Incretin hormone and insulin responses to oral vs intravenous lipid administration in humans. J Clin Endocrinol Metab 96:2519–2524
38. Kielgast U, Holst JJ, Madsbad S (2011) Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 60:1599–1607
39. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
40. Utzschneider KM, Prigeon RL, Carr DB et al (2006) Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care 29:356–362
41. Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Prog Biomed 50:253–264
42. Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377
43. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166
44. Al-Sabah S, Al-Fulaij M, Ahmed HA (2014) Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. Eur J Pharmacol 741:311–315
45. Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386
46. Jimenez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J (2013) GLP-1 action and glucose tolerance in participants with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 36:2062–2069
47. Lev-Ran A, Anderson RW (1981) The diagnosis of postprandial hypoglycaemia. Diabetes 30:996–999
48. Mitrakou A, Ryan C, Veneman T et al (1991) Hierarchy of glycaemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 260:E67–E74